FORRESTER
Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation EMEA, held in London and digitally 12–13 October 2023. As technology finds its way into every function of business, the role of the technology organisation and leader has changed. To stay competitive in today’s business environment, tech leaders need to anticipate the future needs of customers and align critical business capabilities — all underpinned by technology — to help their companies capture value and drive business growth.
At this year’s Technology & Innovation EMEA, chief information officers, chief technology officers, chief digital officers, and other technology leaders will learn best practices to help their organisations prioritise the right decisions, accelerate time to value, and deliver successful outcomes for customers and employees. They will also learn how to leverage emerging technologies such as generative AI to drive innovation and improve efficiency.
The event will include several guest keynote speakers, including noted author, Columbia Business School professor, and founder of the Mentora Institute, Hitendra Wadhwa, and Lloyds Banking Group head of digital delivery and strategy, Mitchell Nova, who will share how new technologies can enhance existing architecture platforms to spark transformation. Technology & Innovation EMEA will also honour EMEA recipients of Forrester’s Technology Awards, which recognise organisations that have successfully implemented technology strategies that are outcome-driven and customer-obsessed to accelerate business growth.
Noteworthy keynotes and sessions include:
- Technology’s Role In Driving The Customer-Obsessed Growth Engine. This keynote discusses how tech executives must work with key stakeholders in their organisation to develop strategies that drive customer value and enable, create, and amplify growth.
- Predictions 2024. Generative AI is exponentially gaining momentum within the future of work, editorial, customer experience, and code writing. In this keynote, learn about the next frontier of innovation threats, advantages, and opportunities in the year ahead.
- The Metaverse Hype Is Over. The Real Work Continues. The metaverse does not exist yet, but precursors do, in consumer- and employee-facing scenarios. This session will discuss how companies are reaching consumers in virtual worlds and how they can make use of new environments for employee onboarding, training, and collaboration.
- Fact Vs. Fiction: When Should You Invest In The Next Shiny Thing? Generative AI already has a key place in the enterprise technology portfolio. This session reveals the current state of the latest emerging technologies, what this means for enterprises, and the lessons that leaders can learn from early adopters of these technologies.
- Digital Leaders Must Become Bolder To Plug Skill Gaps. Every organisation is facing skill gaps when tackling their broader digital transformation initiative. This session will discuss how most European business leaders have difficulty finding the digital talent they need and what they can do to combat this challenge.
“Regardless of the economic climate, technology and innovation is essential to driving business growth,” said Pascal Matzke, event host and VP, research director at Forrester. “Since CIOs and the IT organisation have the broadest span of control and visibility across business, processes, and data systems, they are in the best position to see the big picture and help prioritise initiatives that drive growth. At Technology & Innovation EMEA, tech leaders will learn how to develop resilient, adaptive, and creative strategies that inspire innovation, improve customer experiences, and supercharge business outcomes.”
In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Forum; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.
Resources:
- Register to attend Forrester’s Technology & Innovation EMEA 2023 conference.
- View the full agenda and speakers for Technology & Innovation EMEA 2023.
- Learn about Technology & Innovation EMEA sponsorship opportunities.
- Follow @Forrester and #ForrTech for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; 70 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230918409305/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom